| Ellen Bianchi, DO | |
|
1 Genesys Pkwy, Grand Blanc, MI 48439-8065 | |
| (810) 606-5127 | |
| Not Available |
| Full Name | Ellen Bianchi |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 1 Genesys Pkwy, Grand Blanc, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679953889 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 5101021843 (Michigan) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 5101025226 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dickinson County Memorial Hospital | Iron mountain, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dickinson County Healthcare System | 6800784943 | 71 |
News Archive
You're faced with a big decision so your second brain provides what's normally referred to as 'gut instinct', but how did this sensation reach you before it was too late?
The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives.
MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
› Verified 7 days ago
| Entity Name | Dickinson County Healthcare System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891751186 PECOS PAC ID: 6800784943 Enrollment ID: O20040310000583 |
News Archive
You're faced with a big decision so your second brain provides what's normally referred to as 'gut instinct', but how did this sensation reach you before it was too late?
The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives.
MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ellen Bianchi, DO Po Box 549, Iron Mountain, MI 49801-0549 Ph: () - | Ellen Bianchi, DO 1 Genesys Pkwy, Grand Blanc, MI 48439-8065 Ph: (810) 606-5127 |
News Archive
You're faced with a big decision so your second brain provides what's normally referred to as 'gut instinct', but how did this sensation reach you before it was too late?
The new BSR guidelines make a number of specific recommendations for the use of standard and/or biologic disease modifying anti-rheumatic drugs (DMARDs), providing crucial advice for clinicians, obstetricians and midwives.
MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.
› Verified 7 days ago
Thomas C. Wright, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1595 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-9190 Fax: 810-606-9400 | |
Dr. Kendra Lynn Johnson, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5933 Woodfield Pkwy, Grand Blanc, MI 48439 Phone: 248-563-3231 | |
Jared Matthew Floch, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5127 | |
Julianna Friesen, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5127 | |
Dr. Bridger Martin West, DO, MHA Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Gme Dept, Grand Blanc, MI 48439 Phone: 810-606-5127 Fax: 810-606-5990 | |
Keith A. Heslinger, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1595 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-9190 Fax: 810-606-9400 | |
Kayla Rose Weston, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 219-246-7589 |